860518P

C18 Ceramide (d18:1/18:0)

Avanti Research^™ - A Croda Brand

• Synonym(e): N-stearoyl-D-erythro-sphingosine
• Empirische Formel (Hill-System): C₃₆H₇₁NO₃
• CAS-Nummer: 2304-81-6
• Molekulargewicht: 565.95
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Form: powder
• Verpackung: pkg of 1 × 10 mg (860518P-10mg); pkg of 1 × 5 mg (860518P-5mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand
• Lipid-Typ: sphingolipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
• InChI: 1S/C36H71NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,34-35,38-39H,3-28,30,32-33H2,1-2H3,(H,37,40)/b31-29+/t34-,35+/m0/s1
• InChIKey: VODZWWMEJITOND-NXCSZAMKSA-N

Beschreibung

Allgemeine Beschreibung

C18 Ceramide (d18:1/18:0) synthesis is catalyzed by ceramide synthase (CERS) 1 and 5. It is a component of cellular membrane and has low gel forming ability compared to unsaturated ceramide.

Anwendung

C18 Ceramide (d18:1/18:0) has been used:

• to induce apoptosis in Manduca embryonic cell line (MRRL-CH1)
• as a standard to quantify ceramide from liver tissue using liquid chromatography-mass spectrometry
• to inhibit ceramidase in human embryonic kidney cells (HEK29) with β-glucocerebrosidase (GCase) mutation

Biochem./physiol. Wirkung

C18 Ceramide based derivatives are present in low levels during neurodegeneration. It favors endoplasmic reticulum based stress and autophagy in glioma cells. Low levels of C18-ceramide are implicated in human head and neck squamous cell carcinoma. C18 ceramide may inhibit tumor progression.

Verpackung

5 mL Amber Glass Screw Cap Vial (860518P-10mg)

5 mL Amber Glass Screw Cap Vial (860518P-5mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable